دورية أكاديمية
أعرض في EDS

Peganum harmala Alkaloids Self-Assembled Supramolecular Nanocapsules with Enhanced Antioxidant and Cytotoxic Activities.

التفاصيل البيبلوغرافية
العنوان: Peganum harmala Alkaloids Self-Assembled Supramolecular Nanocapsules with Enhanced Antioxidant and Cytotoxic Activities.
المؤلفون: Fahmy SA; Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC Avenue, P.O. Box 74, New Cairo 11835, Egypt.; School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, R5 New Garden City, New Capital, Cairo 11835, Egypt., Issa MY; Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt., Saleh BM; Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC Avenue, P.O. Box 74, New Cairo 11835, Egypt., Meselhy MR; Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt., Azzazy HME; Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, AUC Avenue, P.O. Box 74, New Cairo 11835, Egypt.
المصدر: ACS omega [ACS Omega] 2021 Apr 27; Vol. 6 (18), pp. 11954-11963. Date of Electronic Publication: 2021 Apr 27 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101691658 Publication Model: eCollection Cited Medium: Internet ISSN: 2470-1343 (Electronic) Linking ISSN: 24701343 NLM ISO Abbreviation: ACS Omega Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Washington, D.C. : American Chemical Society, [2016]-
مستخلص: Amphiphilic macrocycles, such as p -sulfonatocalix[6]arenes ( p -SC6), have demonstrated great potential in designing synthetic nanovesicles based on self-assembly approaches. These supramolecular nanovesicles are capable of improving the solubility, stability, and biological activity of various drugs. In the present study, the biologically active harmala alkaloid-rich fraction (HARF) was extracted from Peganum harmala L . seeds. Ultraperformance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC/ESI-MS) analysis of HARF revealed 15 alkaloids. The reversed-phase high-performance liquid chromatography (RP-HPLC) analysis revealed three peaks: peganine, harmol, and harmine. The HARF was then encapsulated in p -SC6 nanocapsules employing a thin-film hydration approach. The designed nanocapsules had an average particle size of 264.8 ± 10.6 nm, and a surface charge of -30.3 ± 2.2 mV. They were able to encapsulate 89.3 ± 1.4, 74.4 ± 1.3, and 76.1 ± 1.7% of the three harmala alkaloids; harmine, harmol, and peganine; respectively. The in vitro drug release experiments showed the potential of the designed nanocapsules to release their cargo at a pH of 5.5 (typical of cancerous tissue). The IC 50 values of HARF encapsulated in p -SC6 (H/ p -SC6 nanocapsules) were 5 and 2.7 μg/mL against ovarian cancer cells (SKOV-3) and breast adenocarcinoma cells (MCF-7), respectively. The prepared nanocapsules were found to be biocompatible when tested on human skin fibroblasts. Additionally, the antioxidant activity of the designed nanocapsules was 5 times that of the free powder fraction; the IC 50 of the H/ p -SC6 nanocapsules was 30.1 ± 1.3 μg/mL, and that of the HARF was 169.3 ± 7.2 μg/mL. In conclusion, encapsulation of P. harmala alkaloid-rich fraction into self-assembled p -SC6 significantly increases its antioxidant and cytotoxic activities.
Competing Interests: The authors declare no competing financial interest.
(© 2021 The Authors. Published by American Chemical Society.)
References: Nanomaterials (Basel). 2021 Apr 09;11(4):. (PMID: 33918743)
Biotechnol Rep (Amst). 2015 Oct 27;8:138-143. (PMID: 28352583)
J Mater Chem B. 2018 Jul 21;6(27):4486-4501. (PMID: 32254666)
Chem Asian J. 2017 Mar 16;12(6):679-689. (PMID: 28112869)
Colloids Surf B Biointerfaces. 2017 Oct 1;158:93-101. (PMID: 28683347)
Biomaterials. 2012 Dec;33(35):9080-6. (PMID: 22981077)
J Pharm Biomed Anal. 2013 Nov;85:162-8. (PMID: 23948761)
Nanoscale. 2017 Sep 14;9(35):13142-13152. (PMID: 28849826)
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:73-79. (PMID: 30149297)
Nat Protoc. 2006;1(3):1112-6. (PMID: 17406391)
Int J Nanomedicine. 2012;7:5249-58. (PMID: 23055732)
Drug Des Devel Ther. 2015 Jun 02;9:2831-8. (PMID: 26082613)
Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1440-1451. (PMID: 27822958)
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Mar 15;193:528-536. (PMID: 29306207)
Int J Pharm. 2008 Sep 1;361(1-2):56-63. (PMID: 18573626)
J Nat Prod. 2020 Mar 27;83(3):770-803. (PMID: 32162523)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Chemistry. 2013 Jun 10;19(24):7931-6. (PMID: 23589382)
Crit Rev Ther Drug Carrier Syst. 2003;20(5):357-403. (PMID: 14959789)
Front Bioeng Biotechnol. 2019 Oct 01;7:238. (PMID: 31632958)
Rev Physiol Biochem Pharmacol. 2003;146:1-54. (PMID: 12605304)
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):599-604. (PMID: 22146623)
BMB Rep. 2010 Dec;43(12):824-9. (PMID: 21189160)
Food Chem. 2012 Sep 15;134(2):1096-105. (PMID: 23107733)
Pharmaceutics. 2020 Sep 10;12(9):. (PMID: 32927897)
Curr Med Chem. 2001 Oct;8(12):1467-86. (PMID: 11562277)
Pharmaceutics. 2019 Jun 20;11(6):. (PMID: 31226856)
Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:501-8. (PMID: 26254603)
Nat Rev Cancer. 2002 Nov;2(11):850-61. (PMID: 12415255)
Curr Med Chem. 2007;14(4):479-500. (PMID: 17305548)
Cancer Gene Ther. 2016 Jul;23(7):221-8. (PMID: 27199219)
Antioxidants (Basel). 2020 Sep 14;9(9):. (PMID: 32937775)
Food Chem Toxicol. 2017 May;103:261-269. (PMID: 28279698)
Food Chem. 2013 May 1;138(1):414-20. (PMID: 23265506)
Curr Cancer Drug Targets. 2002 Sep;2(3):209-26. (PMID: 12188908)
Cancer Genomics Proteomics. 2006 May-Aug;3(3-4):147-157. (PMID: 31394693)
Food Chem Toxicol. 2010 Mar;48(3):839-45. (PMID: 20036304)
Materials (Basel). 2020 Aug 19;13(17):. (PMID: 32825057)
Molecules. 2020 Dec 14;25(24):. (PMID: 33327642)
Cancer Res. 1989 Aug 15;49(16):4373-84. (PMID: 2545340)
Drug Deliv. 2016 Nov;23(9):3480-3491. (PMID: 27247018)
ACS Omega. 2020 Nov 25;5(48):31456-31466. (PMID: 33324858)
J Asian Nat Prod Res. 2015 May;17(5):595-600. (PMID: 26166311)
Anticancer Res. 1988 May-Jun;8(3):323-7. (PMID: 2839098)
Clin Cancer Res. 2008 Mar 1;14(5):1310-6. (PMID: 18316549)
تواريخ الأحداث: Date Created: 20210531 Latest Revision: 20210601
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8153973
DOI: 10.1021/acsomega.1c00455
PMID: 34056350
قاعدة البيانات: MEDLINE
الوصف
تدمد:2470-1343
DOI:10.1021/acsomega.1c00455